PharmaCyte Biotech (PMCB) director details option grant, RSU vesting changes

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. reported equity award activity for director Wayne R. Walker. On 12/12/2025, 37,500 shares of common stock were acquired at $0 per share, and 16,875 shares were disposed of at $1.02 per share to satisfy tax liability upon vesting of restricted stock units, leaving 20,625 shares of common stock directly owned.

Walker also reported receiving 63,233 stock options on 04/25/2025 with an exercise price of $1.22 per share, expiring on 04/24/2035 and covering 63,233 shares of common stock. These options will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service, and the company notes the transaction was reported late due to an inadvertent administrative error, not any error of Mr. Walker.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider WALKER WAYNE REMELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	37,500	$0.00	--
Tax Withholding	Common Stock	16,875	$1.02	$17K
Grant/Award	Stock Option (Right to Buy)	63,233	$0.00	--

Holdings After Transaction: Common Stock — 37,500 shares (Direct); Stock Option (Right to Buy) — 63,233 shares (Direct)

Footnotes (1)

1. Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALKER WAYNE REMELL

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NV 89169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
04/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		37,500	A	$0	37,500	D
Common Stock	12/12/2025		F		16,875(1)	D	$1.02	20,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.22	04/25/2025		A		63,233		(2)	04/24/2035	Common Stock	63,233	$0	63,233	D

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

2. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

	/s/ Wayne R. Walker	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PharmaCyte Biotech (PMCB) report?

The report shows director Wayne R. Walker acquiring 37,500 shares of common stock at $0 per share and 16,875 shares disposed of at $1.02 per share to cover tax withholding on restricted stock unit vesting, resulting in 20,625 shares directly owned.

How many PharmaCyte Biotech shares does the director own after the transaction?

After the reported transactions, director Wayne R. Walker beneficially owns 20,625 shares of PharmaCyte Biotech common stock in direct ownership.

What stock options did the PharmaCyte Biotech director receive?

On 04/25/2025, Walker received 63,233 stock options with an exercise price of $1.22 per share, expiring on 04/24/2035, each option corresponding to one share of PharmaCyte Biotech common stock.

When will the director’s PharmaCyte Biotech stock options vest?

The 63,233 stock options will vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders, subject to the continued service of Mr. Walker.

Why were some PharmaCyte Biotech shares shown as disposed of in the filing?

The 16,875 shares marked as disposed of represent shares withheld by PharmaCyte Biotech to satisfy Mr. Walker’s tax liability upon vesting of restricted stock units and do not reflect an open-market sale.

Why was the PharmaCyte Biotech option grant reported late?

The company explains that the option grant transaction was reported late due to an inadvertent administrative error and states it was not due to any error by Mr. Walker.